Cryolife (NYSE:CRY) issued an update on its FY20 earnings guidance on Thursday morning. The company provided earnings per share guidance of $0.15-0.17 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $0.38. The company issued revenue guidance of $292-298 million, compared to the consensus revenue estimate of $299.19 million.Cryolife also updated its FY 2020
After-Hours guidance to 0.15-0.17 EPS.
Several brokerages have weighed in on CRY. Zacks Investment Research cut Cryolife from a buy rating to a hold rating in a report on Wednesday, October 23rd. Oppenheimer assumed coverage on shares of Cryolife in a research note on Tuesday, October 22nd. They issued an outperform rating and a $34.00 target price on the stock. Canaccord Genuity cut shares of Cryolife from a buy rating to a hold rating and lowered their price target for the stock from $32.00 to $29.00 in a research report on Friday. First Analysis downgraded shares of Cryolife from a strong-buy rating to an outperform rating in a research note on Friday. Finally, Needham & Company LLC boosted their price target on shares of Cryolife from $30.00 to $38.00 and gave the stock a buy rating in a research note on Wednesday, January 29th. Three analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. Cryolife presently has an average rating of Buy and an average price target of $32.00.
Shares of CRY stock traded down $2.77 during trading hours on Friday, reaching $27.53. The company had a trading volume of 993,639 shares. Cryolife has a 1-year low of $20.76 and a 1-year high of $33.00. The company has a 50 day moving average of $29.08 and a 200 day moving average of $26.60.
In other news, VP Jean F. Holloway sold 8,458 shares of the company’s stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $30.00, for a total value of $253,740.00. Following the completion of the sale, the vice president now directly owns 67,322 shares of the company’s stock, valued at approximately $2,019,660. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Ronald D. Mccall sold 4,000 shares of the stock in a transaction that occurred on Tuesday, November 19th. The shares were sold at an average price of $24.56, for a total transaction of $98,240.00. In the last 90 days, insiders have sold 19,837 shares of company stock worth $536,927. Company insiders own 4.40% of the company’s stock.
Cryolife Company Profile
CryoLife, Inc, together with its subsidiaries, manufactures, processes, and distributes medical devices and implantable human tissues for use in cardiac and vascular surgeries worldwide. The company operates in two segments, Medical Devices and Preservation Services. It offers BioGlue, an agent for cross-linking proteins for cardiac, vascular, pulmonary, and general surgical applications; On-X mechanical heart valves for aortic and mitral indications; cardiac preservation services; PhotoFix, a bovine pericardial patch for use in cardiac and vascular repairing activities; and PerClot, an absorbable powdered hemostat for use in surgical procedures, including cardiac, vascular, orthopedic, neurological, gynecological, ENT, and trauma surgeries.
Receive News & Ratings for Cryolife Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cryolife and related companies with MarketBeat.com's FREE daily email newsletter.